Which has stronger valuation & earnings, STEM or CXDO?

Stem has higher revenue and earnings than Crexendo. Stem is trading at a lower price-to-earnings ratio than Crexendo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Stem $156.27M 0.35 $137.76M -$8.49 N/A Crexendo $68.17M 3.09 $5.07M $0.14 45.21

Is STEM or CXDO more profitable?

Crexendo has a net margin of 5.31% compared to Stem's net margin of -49.37%. Crexendo's return on equity of 14.34% beat Stem's return on equity. Company Net Margins Return on Equity Return on Assets Stem -49.37% N/A -21.85% Crexendo 5.31% 14.34% 11.44%

Does the media prefer STEM or CXDO?

In the previous week, Stem had 13 more articles in the media than Crexendo. MarketBeat recorded 17 mentions for Stem and 4 mentions for Crexendo. Crexendo's average media sentiment score of 0.84 beat Stem's score of 0.23 indicating that Crexendo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stem 2 Very Positive mention(s) 5 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Crexendo 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, EXFY or STEM?

Stem has higher revenue and earnings than Expensify. Expensify is trading at a lower price-to-earnings ratio than Stem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Expensify $138.10M 1.51 -$21.39M -$0.17 N/A Stem $156.27M 0.35 $137.76M -$8.49 N/A

Is EXFY or STEM more profitable?

Expensify has a net margin of -11.31% compared to Stem's net margin of -49.37%. Stem's return on equity of 0.00% beat Expensify's return on equity. Company Net Margins Return on Equity Return on Assets Expensify -11.31% -11.54% -8.34% Stem -49.37% N/A -21.85%

Which has higher earnings & valuation, STEM or EGAN?

Stem has higher revenue and earnings than eGain. Stem is trading at a lower price-to-earnings ratio than eGain, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Stem $156.27M 0.35 $137.76M -$8.49 N/A eGain $88.43M 2.22 $32.25M $1.38 5.18

Is STEM or EGAN more profitable?

eGain has a net margin of 41.68% compared to Stem's net margin of -49.37%. eGain's return on equity of 12.56% beat Stem's return on equity. Company Net Margins Return on Equity Return on Assets Stem -49.37% N/A -21.85% eGain 41.68% 12.56% 7.48%

Does the media favor STEM or EGAN?

In the previous week, Stem had 16 more articles in the media than eGain. MarketBeat recorded 17 mentions for Stem and 1 mentions for eGain. Stem's average media sentiment score of 0.23 beat eGain's score of -0.71 indicating that Stem is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stem 2 Very Positive mention(s) 5 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral eGain 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts recommend ZSQR or STEM?

Stem has a consensus price target of $7.45, suggesting a potential upside of 31.86%. Given Stem's stronger consensus rating and higher possible upside, analysts plainly believe Stem is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Stem 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Is ZSQR or STEM more profitable?

Stem has a net margin of -49.37% compared to Coeptis Therapeutics' net margin of -773.72%. Stem's return on equity of 0.00% beat Coeptis Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Coeptis Therapeutics -773.72% -49.45% -46.88% Stem -49.37% N/A -21.85%

Do analysts recommend PERF or STEM?

Stem has a consensus target price of $7.45, suggesting a potential upside of 31.86%. Given Stem's stronger consensus rating and higher probable upside, analysts clearly believe Stem is more favorable than Perfect. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Perfect 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Stem 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Which has preferable earnings and valuation, PERF or STEM?

Stem has higher revenue and earnings than Perfect. Stem is trading at a lower price-to-earnings ratio than Perfect, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Perfect $69.15M 2.79 $4.64M $0.06 31.58 Stem $156.27M 0.35 $137.76M -$8.49 N/A

Is PERF or STEM more profitable?

Perfect has a net margin of 8.13% compared to Stem's net margin of -49.37%. Perfect's return on equity of 3.73% beat Stem's return on equity. Company Net Margins Return on Equity Return on Assets Perfect 8.13% 3.73% 2.98% Stem -49.37% N/A -21.85%

Does the media favor PERF or STEM?

In the previous week, Stem had 16 more articles in the media than Perfect. MarketBeat recorded 17 mentions for Stem and 1 mentions for Perfect. Perfect's average media sentiment score of 1.17 beat Stem's score of 0.23 indicating that Perfect is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perfect 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stem 2 Very Positive mention(s) 5 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral

Stem (STEM) Competitors

$5.65 +0.19 (+3.48%)

As of 12:51 PM Eastern

Compare

STEM vs. CXDO, EXFY, EGAN, ZSQR, and PERF

Should you buy Stem stock or one of its competitors? Stem's main competitors and comparable companies include Crexendo (CXDO), Expensify (EXFY), eGain (EGAN), Coeptis Therapeutics (ZSQR), and Perfect (PERF). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "application software" industry.

How does Stem compare to Crexendo?

Stem (NYSE:STEM) and Crexendo (NASDAQ:CXDO) are both small-cap technology companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

Stem has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, Crexendo has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

Stem presently has a consensus target price of $7.45, suggesting a potential upside of 31.86%. Crexendo has a consensus target price of $10.50, suggesting a potential upside of 65.88%. Given Crexendo's stronger consensus rating and higher probable upside, analysts plainly believe Crexendo is more favorable than Stem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stem	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Crexendo	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

61.6% of Stem shares are held by institutional investors. Comparatively, 9.5% of Crexendo shares are held by institutional investors. 5.1% of Stem shares are held by company insiders. Comparatively, 47.2% of Crexendo shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Crexendo has a net margin of 5.31% compared to Stem's net margin of -49.37%. Crexendo's return on equity of 14.34% beat Stem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stem	-49.37%	N/A	-21.85%
Crexendo	5.31%	14.34%	11.44%

In the previous week, Stem had 13 more articles in the media than Crexendo. MarketBeat recorded 17 mentions for Stem and 4 mentions for Crexendo. Crexendo's average media sentiment score of 0.84 beat Stem's score of 0.23 indicating that Crexendo is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stem	2 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
Crexendo	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Stem has higher revenue and earnings than Crexendo. Stem is trading at a lower price-to-earnings ratio than Crexendo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stem	$156.27M	0.35	$137.76M	-$8.49	N/A
Crexendo	$68.17M	3.09	$5.07M	$0.14	45.21

Summary

Crexendo beats Stem on 11 of the 16 factors compared between the two stocks.

How does Stem compare to Expensify?

Expensify (NASDAQ:EXFY) and Stem (NYSE:STEM) are both small-cap technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

68.4% of Expensify shares are owned by institutional investors. Comparatively, 61.6% of Stem shares are owned by institutional investors. 11.7% of Expensify shares are owned by company insiders. Comparatively, 5.1% of Stem shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Stem has higher revenue and earnings than Expensify. Expensify is trading at a lower price-to-earnings ratio than Stem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Expensify	$138.10M	1.51	-$21.39M	-$0.17	N/A
Stem	$156.27M	0.35	$137.76M	-$8.49	N/A

In the previous week, Stem had 17 more articles in the media than Expensify. MarketBeat recorded 17 mentions for Stem and 0 mentions for Expensify. Stem's average media sentiment score of 0.23 beat Expensify's score of 0.00 indicating that Stem is being referred to more favorably in the news media.

Company	Overall Sentiment
Expensify	Neutral
Stem	Neutral

Expensify has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market. Comparatively, Stem has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market.

Expensify has a net margin of -11.31% compared to Stem's net margin of -49.37%. Stem's return on equity of 0.00% beat Expensify's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Expensify	-11.31%	-11.54%	-8.34%
Stem	-49.37%	N/A	-21.85%

Expensify currently has a consensus price target of $3.00, indicating a potential upside of 13.85%. Stem has a consensus price target of $7.45, indicating a potential upside of 31.86%. Given Stem's higher possible upside, analysts clearly believe Stem is more favorable than Expensify.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Expensify	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Stem	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Expensify beats Stem on 9 of the 16 factors compared between the two stocks.

How does Stem compare to eGain?

Stem (NYSE:STEM) and eGain (NASDAQ:EGAN) are both small-cap technology companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

Stem has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market. Comparatively, eGain has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market.

In the previous week, Stem had 16 more articles in the media than eGain. MarketBeat recorded 17 mentions for Stem and 1 mentions for eGain. Stem's average media sentiment score of 0.23 beat eGain's score of -0.71 indicating that Stem is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stem	2 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
eGain	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

61.6% of Stem shares are owned by institutional investors. Comparatively, 53.9% of eGain shares are owned by institutional investors. 5.1% of Stem shares are owned by company insiders. Comparatively, 38.7% of eGain shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

eGain has a net margin of 41.68% compared to Stem's net margin of -49.37%. eGain's return on equity of 12.56% beat Stem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stem	-49.37%	N/A	-21.85%
eGain	41.68%	12.56%	7.48%

Stem currently has a consensus target price of $7.45, suggesting a potential upside of 31.86%. eGain has a consensus target price of $15.25, suggesting a potential upside of 113.44%. Given eGain's stronger consensus rating and higher possible upside, analysts clearly believe eGain is more favorable than Stem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stem	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
eGain	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

Stem has higher revenue and earnings than eGain. Stem is trading at a lower price-to-earnings ratio than eGain, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stem	$156.27M	0.35	$137.76M	-$8.49	N/A
eGain	$88.43M	2.22	$32.25M	$1.38	5.18

Summary

eGain beats Stem on 10 of the 16 factors compared between the two stocks.

How does Stem compare to Coeptis Therapeutics?

Coeptis Therapeutics (NASDAQ:ZSQR) and Stem (NYSE:STEM) are both small-cap technology companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Stem has a net margin of -49.37% compared to Coeptis Therapeutics' net margin of -773.72%. Stem's return on equity of 0.00% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%
Stem	-49.37%	N/A	-21.85%

Stem has higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Stem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	$1.36M	157.44	-$11.92M	-$1.63	N/A
Stem	$156.27M	0.35	$137.76M	-$8.49	N/A

Coeptis Therapeutics has a beta of -0.19, indicating that its stock price is 119% less volatile than the broader market. Comparatively, Stem has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market.

13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 61.6% of Stem shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by company insiders. Comparatively, 5.1% of Stem shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Stem had 16 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 17 mentions for Stem and 1 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 1.00 beat Stem's score of 0.23 indicating that Coeptis Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Coeptis Therapeutics	Positive
Stem	Neutral

Stem has a consensus price target of $7.45, suggesting a potential upside of 31.86%. Given Stem's stronger consensus rating and higher possible upside, analysts plainly believe Stem is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Stem	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Stem beats Coeptis Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Stem compare to Perfect?

Perfect (NYSE:PERF) and Stem (NYSE:STEM) are both small-cap technology companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Perfect has a net margin of 8.13% compared to Stem's net margin of -49.37%. Perfect's return on equity of 3.73% beat Stem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perfect	8.13%	3.73%	2.98%
Stem	-49.37%	N/A	-21.85%

Stem has a consensus target price of $7.45, suggesting a potential upside of 31.86%. Given Stem's stronger consensus rating and higher probable upside, analysts clearly believe Stem is more favorable than Perfect.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perfect	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Stem	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

61.6% of Stem shares are owned by institutional investors. 5.1% of Stem shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Perfect has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market. Comparatively, Stem has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market.

In the previous week, Stem had 16 more articles in the media than Perfect. MarketBeat recorded 17 mentions for Stem and 1 mentions for Perfect. Perfect's average media sentiment score of 1.17 beat Stem's score of 0.23 indicating that Perfect is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perfect	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stem	2 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral

Stem has higher revenue and earnings than Perfect. Stem is trading at a lower price-to-earnings ratio than Perfect, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perfect	$69.15M	2.79	$4.64M	$0.06	31.58
Stem	$156.27M	0.35	$137.76M	-$8.49	N/A

Summary

Stem beats Perfect on 8 of the 15 factors compared between the two stocks.

Get Stem News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STEM vs. The Competition

Export

Metric	Stem	Software Industry	Technology Sector	NYSE Exchange
Market Cap	$54.41M	$15.49B	$29.00B	$24.24B
Dividend Yield	N/A	3.42%	2.74%	3.70%
P/E Ratio	-0.67	126.49	72.33	30.22
Price / Sales	0.35	1,283.84	591.13	17.53
Price / Cash	N/A	45.05	49.03	19.80
Price / Book	-0.19	8.52	7.90	4.90
Net Income	$137.76M	$434.52M	$678.06M	$1.07B
7 Day Performance	-2.69%	2.92%	0.19%	0.53%
1 Month Performance	3.37%	6.89%	4.20%	2.89%
1 Year Performance	-65.72%	5.47%	188.54%	14.99%

Stem Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STEM Stem	2.6274 of 5 stars	$5.65 +3.5%	$7.45 +31.9%	-67.5%	$54.41M	$156.27M	N/A	660	Gap Up
CXDO Crexendo	4.3195 of 5 stars	$6.27 -1.9%	$10.50 +67.5%	+2.8%	$212.49M	$68.17M	44.79	120
EXFY Expensify	1.4695 of 5 stars	$2.72 +3.0%	$3.00 +10.3%	+48.6%	$208.39M	$138.10M	N/A	140
EGAN eGain	1.898 of 5 stars	$7.14 -2.2%	$15.25 +113.6%	+11.6%	$200.39M	$88.43M	5.17	690
ZSQR Coeptis Therapeutics	0.5639 of 5 stars	$3.66 +0.3%	N/A	-72.8%	$193.45M	$1.36M	N/A	2	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:STEM) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stem (STEM) Competitors